Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：68頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2014’, provides an overview of the Venous Leg Ulcers (Crural ulcer)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Venous Leg Ulcers (Crural ulcer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Leg Ulcers (Crural ulcer) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Venous Leg Ulcers (Crural ulcer) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Venous Leg Ulcers (Crural ulcer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Venous Leg Ulcers (Crural ulcer) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Venous Leg Ulcers (Crural ulcer)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2014’, provides an overview of the Venous Leg Ulcers (Crural ulcer)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Venous Leg Ulcers (Crural ulcer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Leg Ulcers (Crural ulcer) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Venous Leg Ulcers (Crural ulcer) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Venous Leg Ulcers (Crural ulcer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Venous Leg Ulcers (Crural ulcer) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Venous Leg Ulcers (Crural ulcer)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Venous Leg Ulcers (Crural ulcer) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Venous Leg Ulcers (Crural ulcer) Overview 7
Therapeutics Development 8
Pipeline Products for Venous Leg Ulcers (Crural ulcer) - Overview 8
Pipeline Products for Venous Leg Ulcers (Crural ulcer) - Comparative Analysis 9
Venous Leg Ulcers (Crural ulcer) - Therapeutics under Development by Companies 10
Venous Leg Ulcers (Crural ulcer) - Therapeutics under Investigation by Universities/Institutes 12
Venous Leg Ulcers (Crural ulcer) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Venous Leg Ulcers (Crural ulcer) - Products under Development by Companies 17
Venous Leg Ulcers (Crural ulcer) - Products under Investigation by Universities/Institutes 18
Venous Leg Ulcers (Crural ulcer) - Companies Involved in Therapeutics Development 19
Smith & Nephew Plc 19
RegeneRx Biopharmaceuticals, Inc. 20
CytoTools AG 21
FirstString Research, Inc. 22
CoDa Therapeutics, Inc. 23
Adocia 24
Intralytix, Inc. 25
Pergamum AB 26
Venous Leg Ulcers (Crural ulcer) - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
HP-802247 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
RGN-137 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
DermaPro CI-05 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CODA-001 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Granexin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
LL-37 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Autologous Bone Marrow Derived Cells - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
WPP-201 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Biochaperone PDGF-BB - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
RGN-137 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Venous Leg Ulcers (Crural ulcer) - Recent Pipeline Updates 52
Venous Leg Ulcers (Crural ulcer) - Dormant Projects 58
Venous Leg Ulcers (Crural ulcer) - Discontinued Products 59
Venous Leg Ulcers (Crural ulcer) - Product Development Milestones 60
Featured News & Press Releases 60
Oct 10, 2013: Pergamum announces final data from Phase I/II study of LL-37 in patients with chronic leg ulcers 60
Apr 19, 2013: Pergamum Reaches Last-Patient-Last-Visit In Phase I/II Trial Of LL-37 For Treatment Of Venous Leg Ulcers 61
Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers 61
Sep 11, 2012: Healthpoint Biotherapeutics Initiates Phase III Study Of Investigational Cell-Based Therapy For Venous Leg Ulcers 61
Sep 11, 2012: Pergamum Announces Dosing Of First Patient In Phase I/II trial Of LL-37 For Hard-to-heal Wounds 62
Aug 02, 2012: Healthpoint Biotherapeutics Announces Publication Of Phase IIb Study Results Of Investigational Cell-Based Therapy In Lancet 63
Jul 25, 2012: Healthpoint Biotherapeutics Announces Phase II Trial Results Of HP802-247 For Venous Leg Ulcers 63
Aug 04, 2011: Healthpoint Biotherapeutics Announces Positive Results From Phase IIb Trial Of HP802-247 In Venous Leg Ulcers 64
Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results 65
Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 68
Disclaimer 68
List of Tables
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2014 8
Number of Products under Development for Venous Leg Ulcers (Crural ulcer) - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Comparative Analysis by Unknown Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Venous Leg Ulcers (Crural ulcer) - Pipeline by Smith & Nephew Plc, H1 2014 19
Venous Leg Ulcers (Crural ulcer) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2014 20
Venous Leg Ulcers (Crural ulcer) - Pipeline by CytoTools AG, H1 2014 21
Venous Leg Ulcers (Crural ulcer) - Pipeline by FirstString Research, Inc., H1 2014 22
Venous Leg Ulcers (Crural ulcer) - Pipeline by CoDa Therapeutics, Inc., H1 2014 23
Venous Leg Ulcers (Crural ulcer) - Pipeline by Adocia, H1 2014 24
Venous Leg Ulcers (Crural ulcer) - Pipeline by Intralytix, Inc., H1 2014 25
Venous Leg Ulcers (Crural ulcer) - Pipeline by Pergamum AB, H1 2014 26
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 33
Number of Products by Stage and Route of Administration, H1 2014 35
Number of Products by Stage and Molecule Type, H1 2014 37
Venous Leg Ulcers (Crural ulcer) Therapeutics - Recent Pipeline Updates, H1 2014 52
Venous Leg Ulcers (Crural ulcer) - Dormant Projects, H1 2014 58
Venous Leg Ulcers (Crural ulcer) - Discontinued Products, H1 2014 59
List of Figures
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2014 8
Number of Products under Development for Venous Leg Ulcers (Crural ulcer) - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 14
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 31
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 32
Number of Products by Top 10 Route of Administration, H1 2014 34
Number of Products by Stage and Top 10 Route of Administration, H1 2014 35
Number of Products by Top 10 Molecule Type, H1 2014 36
Number of Products by Stage and Top 10 Molecule Type, H1 2014 37
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Venous Leg Ulcers (Crural ulcer) Overview 7
Therapeutics Development 8
Pipeline Products for Venous Leg Ulcers (Crural ulcer) - Overview 8
Pipeline Products for Venous Leg Ulcers (Crural ulcer) - Comparative Analysis 9
Venous Leg Ulcers (Crural ulcer) - Therapeutics under Development by Companies 10
Venous Leg Ulcers (Crural ulcer) - Therapeutics under Investigation by Universities/Institutes 12
Venous Leg Ulcers (Crural ulcer) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Venous Leg Ulcers (Crural ulcer) - Products under Development by Companies 17
Venous Leg Ulcers (Crural ulcer) - Products under Investigation by Universities/Institutes 18
Venous Leg Ulcers (Crural ulcer) - Companies Involved in Therapeutics Development 19
Smith & Nephew Plc 19
RegeneRx Biopharmaceuticals, Inc. 20
CytoTools AG 21
FirstString Research, Inc. 22
CoDa Therapeutics, Inc. 23
Adocia 24
Intralytix, Inc. 25
Pergamum AB 26
Venous Leg Ulcers (Crural ulcer) - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
HP-802247 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
RGN-137 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
DermaPro CI-05 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CODA-001 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Granexin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
LL-37 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Autologous Bone Marrow Derived Cells - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
WPP-201 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Biochaperone PDGF-BB - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
RGN-137 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Venous Leg Ulcers (Crural ulcer) - Recent Pipeline Updates 52
Venous Leg Ulcers (Crural ulcer) - Dormant Projects 58
Venous Leg Ulcers (Crural ulcer) - Discontinued Products 59
Venous Leg Ulcers (Crural ulcer) - Product Development Milestones 60
Featured News & Press Releases 60
Oct 10, 2013: Pergamum announces final data from Phase I/II study of LL-37 in patients with chronic leg ulcers 60
Apr 19, 2013: Pergamum Reaches Last-Patient-Last-Visit In Phase I/II Trial Of LL-37 For Treatment Of Venous Leg Ulcers 61
Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers 61
Sep 11, 2012: Healthpoint Biotherapeutics Initiates Phase III Study Of Investigational Cell-Based Therapy For Venous Leg Ulcers 61
Sep 11, 2012: Pergamum Announces Dosing Of First Patient In Phase I/II trial Of LL-37 For Hard-to-heal Wounds 62
Aug 02, 2012: Healthpoint Biotherapeutics Announces Publication Of Phase IIb Study Results Of Investigational Cell-Based Therapy In Lancet 63
Jul 25, 2012: Healthpoint Biotherapeutics Announces Phase II Trial Results Of HP802-247 For Venous Leg Ulcers 63
Aug 04, 2011: Healthpoint Biotherapeutics Announces Positive Results From Phase IIb Trial Of HP802-247 In Venous Leg Ulcers 64
Mar 26, 2009: RegeneRx Reports Phase II Venous Stasis Trial Results 65
Feb 26, 2009: RegeneRx Updates On Phase II Venous Stasis Trial 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 68
Disclaimer 68
List of Tables
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2014 8
Number of Products under Development for Venous Leg Ulcers (Crural ulcer) - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Comparative Analysis by Unknown Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Venous Leg Ulcers (Crural ulcer) - Pipeline by Smith & Nephew Plc, H1 2014 19
Venous Leg Ulcers (Crural ulcer) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2014 20
Venous Leg Ulcers (Crural ulcer) - Pipeline by CytoTools AG, H1 2014 21
Venous Leg Ulcers (Crural ulcer) - Pipeline by FirstString Research, Inc., H1 2014 22
Venous Leg Ulcers (Crural ulcer) - Pipeline by CoDa Therapeutics, Inc., H1 2014 23
Venous Leg Ulcers (Crural ulcer) - Pipeline by Adocia, H1 2014 24
Venous Leg Ulcers (Crural ulcer) - Pipeline by Intralytix, Inc., H1 2014 25
Venous Leg Ulcers (Crural ulcer) - Pipeline by Pergamum AB, H1 2014 26
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 33
Number of Products by Stage and Route of Administration, H1 2014 35
Number of Products by Stage and Molecule Type, H1 2014 37
Venous Leg Ulcers (Crural ulcer) Therapeutics - Recent Pipeline Updates, H1 2014 52
Venous Leg Ulcers (Crural ulcer) - Dormant Projects, H1 2014 58
Venous Leg Ulcers (Crural ulcer) - Discontinued Products, H1 2014 59
List of Figures
Number of Products under Development for Venous Leg Ulcers (Crural ulcer), H1 2014 8
Number of Products under Development for Venous Leg Ulcers (Crural ulcer) - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 14
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 31
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 32
Number of Products by Top 10 Route of Administration, H1 2014 34
Number of Products by Stage and Top 10 Route of Administration, H1 2014 35
Number of Products by Top 10 Molecule Type, H1 2014 36
Number of Products by Stage and Top 10 Molecule Type, H1 2014 37
